JP2020513810A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020513810A5 JP2020513810A5 JP2019550762A JP2019550762A JP2020513810A5 JP 2020513810 A5 JP2020513810 A5 JP 2020513810A5 JP 2019550762 A JP2019550762 A JP 2019550762A JP 2019550762 A JP2019550762 A JP 2019550762A JP 2020513810 A5 JP2020513810 A5 JP 2020513810A5
- Authority
- JP
- Japan
- Prior art keywords
- mutant
- yap protein
- composition
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000006467 substitution reaction Methods 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 210000004413 cardiac myocyte Anatomy 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 230000001172 regenerating effect Effects 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 229930186657 Lat Natural products 0.000 claims 1
- 241001522306 Serinus serinus Species 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 210000005003 heart tissue Anatomy 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022105207A JP7461071B2 (ja) | 2017-03-14 | 2022-06-30 | クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ |
| JP2024040081A JP2024073571A (ja) | 2017-03-14 | 2024-03-14 | クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471204P | 2017-03-14 | 2017-03-14 | |
| US62/471,204 | 2017-03-14 | ||
| PCT/US2018/022496 WO2018170172A1 (en) | 2017-03-14 | 2018-03-14 | Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022105207A Division JP7461071B2 (ja) | 2017-03-14 | 2022-06-30 | クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020513810A JP2020513810A (ja) | 2020-05-21 |
| JP2020513810A5 true JP2020513810A5 (enExample) | 2021-04-15 |
Family
ID=63523973
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550762A Pending JP2020513810A (ja) | 2017-03-14 | 2018-03-14 | クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ |
| JP2022105207A Active JP7461071B2 (ja) | 2017-03-14 | 2022-06-30 | クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ |
| JP2024040081A Pending JP2024073571A (ja) | 2017-03-14 | 2024-03-14 | クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022105207A Active JP7461071B2 (ja) | 2017-03-14 | 2022-06-30 | クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ |
| JP2024040081A Pending JP2024073571A (ja) | 2017-03-14 | 2024-03-14 | クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11484553B2 (enExample) |
| EP (1) | EP3595642A4 (enExample) |
| JP (3) | JP2020513810A (enExample) |
| CN (2) | CN110520112A (enExample) |
| AU (2) | AU2018234632B2 (enExample) |
| BR (1) | BR112019018912A2 (enExample) |
| CA (1) | CA3056231A1 (enExample) |
| IL (2) | IL308112B2 (enExample) |
| MX (2) | MX2019010986A (enExample) |
| WO (1) | WO2018170172A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018223062A1 (en) * | 2017-06-01 | 2018-12-06 | Baylor College Of Medicine | Dystrophin glycoprotein complex sequesters yap to inhibit cardiomyocyte proliferation |
| US11179479B2 (en) | 2018-01-05 | 2021-11-23 | Animatus Biosciences, Llc | Enhanced cardiomyocyte regeneration |
| WO2021119030A1 (en) * | 2019-12-09 | 2021-06-17 | Animatus Biosciences, Llc | Enhanced cardiomyocyte regeneration |
| US20210324412A1 (en) * | 2020-04-15 | 2021-10-21 | University Of Southern California | Activation of yap signaling for sensory receptor regeneration |
| CN111778281B (zh) * | 2020-07-17 | 2021-04-23 | 四川省人民医院 | 一种视网膜双极细胞病变模型的构建方法及其应用 |
| US12692497B2 (en) * | 2021-10-19 | 2026-07-28 | Animatus Biosciences, Inc. | Cardiac cell proliferation by administering inhibitors of SAV1, NF2, MOB1 and/or mutant SRF |
| CN117547608B (zh) * | 2022-08-03 | 2026-07-21 | 苏州大学 | Yap/taz在制备治疗ed药物中的应用 |
| AU2024217340A1 (en) * | 2023-02-10 | 2025-08-07 | Baylor College Of Medicine | Use of mutant yap for improving cardiac function |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| AU664561B2 (en) | 1991-06-21 | 1995-11-23 | University Of Cincinnati, The | Orally administrable therapeutic proteins and method of making |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| ATE155681T1 (de) | 1992-05-18 | 1997-08-15 | Minnesota Mining & Mfg | Einrichtung zur transmucosalen wirkstoffabgabe |
| US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| TW563139B (en) | 2000-11-30 | 2003-11-21 | Nec Tokin Corp | Magnetic core including magnet for magnetic bias and inductor component using the same |
| US8140593B2 (en) * | 2008-05-15 | 2012-03-20 | Microsoft Corporation | Data viewer management |
| KR101057116B1 (ko) * | 2008-06-17 | 2011-08-16 | 한국과학기술원 | 포유류에서의 분화 조절제 및 분화 조절 방법 |
| WO2013151664A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| WO2015074010A2 (en) | 2013-11-18 | 2015-05-21 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for cardiac regeneration |
| CN103705505A (zh) * | 2013-12-19 | 2014-04-09 | 清华大学深圳研究生院 | 辛伐他汀的新用途 |
| EP3105329A1 (en) | 2014-02-11 | 2016-12-21 | Institut Pasteur | Treatment of cardiac diseases with modulators of the hippo pathway |
| US20170246215A1 (en) | 2014-09-16 | 2017-08-31 | Albert Einstein College Of Medicine, Inc. | Repopulation of organs and tissues using a yap-ert2 fusion protein |
| GB201819659D0 (en) * | 2018-12-03 | 2019-01-16 | Vib Vzw | Cancer regression by inducing a regeneration-like reponse |
-
2018
- 2018-03-14 BR BR112019018912-2A patent/BR112019018912A2/pt unknown
- 2018-03-14 CN CN201880025311.XA patent/CN110520112A/zh active Pending
- 2018-03-14 AU AU2018234632A patent/AU2018234632B2/en active Active
- 2018-03-14 MX MX2019010986A patent/MX2019010986A/es unknown
- 2018-03-14 EP EP18767332.2A patent/EP3595642A4/en active Pending
- 2018-03-14 JP JP2019550762A patent/JP2020513810A/ja active Pending
- 2018-03-14 WO PCT/US2018/022496 patent/WO2018170172A1/en not_active Ceased
- 2018-03-14 CN CN202210859133.9A patent/CN116003564A/zh active Pending
- 2018-03-14 IL IL308112A patent/IL308112B2/en unknown
- 2018-03-14 US US16/491,491 patent/US11484553B2/en active Active
- 2018-03-14 IL IL269187A patent/IL269187B2/en unknown
- 2018-03-14 CA CA3056231A patent/CA3056231A1/en active Pending
-
2019
- 2019-09-13 MX MX2022011881A patent/MX2022011881A/es unknown
-
2022
- 2022-06-30 JP JP2022105207A patent/JP7461071B2/ja active Active
- 2022-09-12 US US17/931,493 patent/US12138284B2/en active Active
-
2024
- 2024-03-14 JP JP2024040081A patent/JP2024073571A/ja active Pending
- 2024-09-09 AU AU2024219497A patent/AU2024219497B2/en active Active
- 2024-10-09 US US18/910,286 patent/US20250073276A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016146198A (ru) | Терапевтические dll4-связывающие белки | |
| MX347200B (es) | Péptidos procoagulantes y sus derivados, y usos para estos. | |
| IN2012DN02981A (enExample) | ||
| JP2017532343A5 (enExample) | ||
| WO2009024327A3 (en) | New proteins for use in human and animal staphylococcus infections | |
| RU2011106744A (ru) | Инсулин, стабилизированный галогеном | |
| WO2011036442A3 (en) | Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders | |
| JP2016509011A5 (enExample) | ||
| NZ602845A (en) | Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof | |
| IL195831A0 (en) | Sparc-derived tumor rejection antigenic peptides and medicaments comprising the same | |
| MX2008009493A (es) | Peptido novedoso y uso del mismo. | |
| JP2020507623A5 (enExample) | ||
| WO2013096868A3 (en) | Saposin-a derived peptides and uses thereof | |
| JP2019525753A5 (enExample) | ||
| EP2589658A4 (en) | PARTICLE POLYPEPTIDE OF THE REIC / DKK-3 PROTEIN | |
| FI3737399T3 (fi) | ATF5-peptidivariantit ja niiden käytöt | |
| JP2006506942A5 (enExample) | ||
| NZ610620A (en) | Inhibitors of apoptosis and uses thereof | |
| IL269187B2 (en) | Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal | |
| JP2011509093A5 (enExample) | ||
| RU2014140231A (ru) | Антимикробные пептиды | |
| EP2465935A3 (en) | Recombinant human interferon-like proteins | |
| JP2017505772A5 (enExample) | ||
| JP2008521795A5 (enExample) | ||
| JP2012518669A5 (enExample) |